The telehealth company Hims & Hers is adding Zepbound and generic liraglutide to its offering of weight-loss drugs.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Secretary Robert F. Kennedy Jr. said he is considering a “regulatory framework” for Medicare and Medicaid to cover GLP-1 ...

LifeMD's growth accelerates with expanded insurance, new health products, and a 43% revenue boost. Click here to read our ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued with the launch of new high-dose vials sold at a $150 discount to its auto ...

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded coverage of costly anti-obesity drugs to more than 7 million Americans on ...

President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...

Doctors say it’s not uncommon for patients to not lose weight on the GLP-1 drugs, even if celebrities are seemingly shedding dozens of pounds. Julia Musto spoke to people frustrated that they are part ...

Prescription weight loss medications, including GLP-1 agonists, orlistat, and Contrave, may be effective for some people. But other lifestyle changes are still necessary for long-term success.